127 related articles for article (PubMed ID: 15496958)
1. Retroviral vector backbone immunogenicity: identification of cytotoxic T-cell epitopes in retroviral vector-packaging sequences.
Kondo E; Akatsuka Y; Nawa A; Kuzushima K; Tsujimura K; Tanimoto M; Kodera Y; Morishima Y; Kuzuya K; Takahashi T
Gene Ther; 2005 Feb; 12(3):252-8. PubMed ID: 15496958
[TBL] [Abstract][Full Text] [Related]
2. Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells.
Heemskerk MH; Hooijberg E; Ruizendaal JJ; van der Weide MM; Kueter E; Bakker AQ; Schumacher TN; Spits H
Cell Immunol; 1999 Jul; 195(1):10-7. PubMed ID: 10433792
[TBL] [Abstract][Full Text] [Related]
3. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
4. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes.
Weijtens ME; Willemsen RA; Hart EH; Bolhuis RL
Gene Ther; 1998 Sep; 5(9):1195-203. PubMed ID: 9930320
[TBL] [Abstract][Full Text] [Related]
5. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.
Hiasa A; Hirayama M; Nishikawa H; Kitano S; Nukaya I; Yu SS; Mineno J; Kato I; Shiku H
Gene Ther; 2008 May; 15(9):695-9. PubMed ID: 18288212
[TBL] [Abstract][Full Text] [Related]
6. Generation of cytotoxic T lymphocytes specific for B-cell acute lymphoblastic leukemia family-shared peptides derived from immunoglobulin heavy chain framework region.
Liu Y; Zhu P; Hu YM
Chin Med J (Engl); 2007 Apr; 120(8):652-7. PubMed ID: 17517179
[TBL] [Abstract][Full Text] [Related]
7. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene.
Vallera DA; Jin N; Baldrica JM; Panoskaltsis-Mortari A; Chen SY; Blazar BR
Cancer Res; 2000 Feb; 60(4):976-84. PubMed ID: 10706113
[TBL] [Abstract][Full Text] [Related]
8. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
9. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
[TBL] [Abstract][Full Text] [Related]
10. Expression mapping using a retroviral vector for CD8+ T cell epitopes: definition of a Mycobacterium tuberculosis peptide presented by H2-Dd.
Aoshi T; Suzuki M; Uchijima M; Nagata T; Koide Y
J Immunol Methods; 2005 Mar; 298(1-2):21-34. PubMed ID: 15847794
[TBL] [Abstract][Full Text] [Related]
11. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes.
van Hall T; van de Rhee NE; Schoenberger SP; Vierboom MP; Verreck FA; Melief CJ; Offringa R
Cancer Res; 1998 Jul; 58(14):3087-93. PubMed ID: 9679975
[TBL] [Abstract][Full Text] [Related]
12. HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.
van der Veken LT; Hoogeboom M; de Paus RA; Willemze R; Falkenburg JH; Heemskerk MH
Gene Ther; 2005 Dec; 12(23):1686-95. PubMed ID: 16034453
[TBL] [Abstract][Full Text] [Related]
13. Efficient transduction and selection of human T-lymphocytes with bicistronic Thy1/HSV1-TK retroviral vector produced by a human packaging cell line.
Lemoine FM; Mesel-Lemoine M; Cherai M; Gallot G; Vié H; Leclercq V; Trébèden-Negre H; Mammès O; Boyer O; Noguiez-Hellin P; Klatzmann D
J Gene Med; 2004 Apr; 6(4):374-86. PubMed ID: 15079812
[TBL] [Abstract][Full Text] [Related]
14. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
[TBL] [Abstract][Full Text] [Related]
15. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
16. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
17. Characterization of host immunity to cytomegalovirus pp150 (UL32).
La Rosa C; Wang Z; Lacey SF; Markel SF; Sharma MC; Martinez J; Lalimarmo MM; Diamond DJ
Hum Immunol; 2005 Feb; 66(2):116-26. PubMed ID: 15694996
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
19. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.
Willemsen RA; Debets R; Hart E; Hoogenboom HR; Bolhuis RL; Chames P
Gene Ther; 2001 Nov; 8(21):1601-8. PubMed ID: 11894998
[TBL] [Abstract][Full Text] [Related]
20. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
